Chimeric antisense oligonucleotide conjugated to α-Tocopherol

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages

  Nishina, Tomoko ^a,b   Numata, Junna ^a   Nishina, Kazutaka ^a,b   Yoshida Tanaka, Kie ^a,b   Nitta, Keiko ^a   Piao, Wenying ^a,b   Iwata, Rintaro ^b,c   Ito, Shingo ^d   Kuwahara, Hiroya ^a,b   Wada, Takeshi ^b,c   Mizusawa, Hidehiro ^a   Yokota, Takanori ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Nucleic acid chemistries Antisense oligonucleotides

Indexed keywords

ALPHA TOCOPHEROL; ANTISENSE OLIGONUCLEOTIDE; CHIMERIC ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEGRADATION; DOSE RESPONSE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; GENE SEQUENCE; GENE SILENCING; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 84922979847     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.72     Document Type: Article

References (32)

1. Kole, R, Krainer, AR and Altman, S (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140.
2. Obika, S, Nanbu, D, Hari, Y, Morio, K, In, Y, Ishida, T et al. (1997). Synthesis of 2 O,4Cmethyleneuridine and cytidine. Novel bicyclic nucleosides having a fixed C3, endo sugar puckering. Tetrahedron Lett 38: 8735-8738.
3. Obika, S, Nanbu, D, Hari, Y, Andoh, J, Morio, K, Doi, T et al. (1998). Stability and structural features of the duplexes containing nucleoside analogues with a fixed Ntype conformation, 2O,4Cmethyleneribonucleosides. Tetrahedron Lett 39: 5401-5404.
4. Singh, SK, Koshkin, AA, Wengel, J and Nielsen, P (1998). LNA (locked nucleic acids): synthesis and highaffinity nucleic acid recognition. Chem Commun 4: 455-456.
5. Freier, SM and Altmann, KH (1997). The ups and downs of nucleic acid duplex stability: structurestability studies on chemicallymodified DNA:RNA duplexes. Nucleic Acids Res 25: 4429-4443.
6. Martin, P (1995). Ein neuer Zugang zu 2OAlkylribonucleosiden und Eigenschaften deren Oligonucleotide. Helv Chim Acta 78: 486-504.
7. Seth, PP, Vasquez, G, Allerson, CA, Berdeja, A, Gaus, H, Kinberger, GA et al. (2010). Synthesis and biophysical evaluation of 2',4'constrained 2'Omethoxyethyl and 2',4'constrained 2'Oethyl nucleic acid analogues. J Org Chem 75: 1569-1581.
8. Murray, S, Ittig, D, Koller, E, Berdeja, A, Chappell, A, Prakash, TP et al. (2012). TricycloDNAmodified oligo2'deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extrahepatic tissues-a comparative study of oligonucleotide length, design and chemistry. Nucleic Acids Res 40: 6135-6143.
9. Monia, BP, Lesnik, EA, Gonzalez, C, Lima, WF, McGee, D, Guinosso, CJ et al. (1993). Evaluation of 2'modified oligonucleotides containing 2'deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268: 14514-14522.
10. Wahlestedt, C, Salmi, P, Good, L, Kela, J, Johnsson, T, Hökfelt, T et al. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 97: 5633-5638.
11. Jiang, K (2013). Biotech comes to its 'antisenses' after hardwon drug approval. Nat Med 19: 252.
12. Crooke, ST and Geary, RS (2013). Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 76: 269-276.
13. Straarup, EM, Fisker, N, Hedtjärn, M, Lindholm, MW, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and nonhuman primates. Nucleic Acids Res 38: 7100-7111.
14. Koller, E, Vincent, TM, Chappell, A, De, S, Manoharan, M and Bennett, CF (2011). Mechanisms of singlestranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 39: 4795-4807.
15. Juliano, RL, Ming, X and Nakagawa, O (2012). Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem 23: 147-157.
16. Kappus, H and Diplock, AT (1992). Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 13: 55-74.
17. Nishina, K, Unno, T, Uno, Y, Kubodera, T, Kanouchi, T, Mizusawa, H et al. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alphatocopherol. Mol Ther 16: 734-740.
18. Uno, Y, Piao, W, Miyata, K, Nishina, K, Mizusawa, H and Yokota, T (2011). Highdensity lipoprotein facilitates in vivo delivery of atocopherolconjugated shortinterfering RNA to the brain. Hum Gene Ther 22: 711-719.
19. Hung, G, Xiao, X, Peralta, R, Bhattacharjee, G, Murray, S, Norris, D et al. (2013). Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther 23: 369-378.
20. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
21. Kuwahara, H, Nishina, K, Yoshida, K, Nishina, T, Yamamoto, M, Saito, Y et al. (2011). Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. Mol Ther 19: 2213-2221.
22. Kanasty, R, Dorkin, JR, Vegas, A and Anderson, D (2013). Delivery materials for siRNA therapeutics. Nat Mater 12: 967-977.
23. Takeshita, F, Minakuchi, Y, Nagahara, S, Honma, K, Sasaki, H, Hirai, K et al. (2005). Efficient delivery of small interfering RNA to bonemetastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182.
24. Rozema, DB, Lewis, DL, Wakefield, DH, Wong, SC, Klein, JJ, Roesch, PL et al. (2007). Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104: 12982-12987.
25. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
26. Kumar, P, Ban, HS, Kim, SS, Wu, H, Pearson, T, Greiner, DL et al. (2008). T cellspecific siRNA delivery suppresses HIV1 infection in humanized mice. Cell 134: 577-586.
27. Jearawiriyapaisarn, N, Moulton, HM, Buckley, B, Roberts, J, Sazani, P, Fucharoen, S et al. (2008). Sustained dystrophin expression induced by peptideconjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629.
28. Prakash, TP, Graham, MJ, Yu, J, Carty, R, Low, A, Chappell, A et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary Nacetyl galactosamine improves potency 10fold in mice. Nucleic Acids Res 42: 8796-8807.
29. Lennox, KA and Behlke, MA (2010). A direct comparison of antimicroRNA oligonucleotide potency. Pharm Res 27: 1788-1799.
30. Tabata, K, Yamaoka, K, Kaibara, A, Suzuki, S, Terakawa, M and Hata, T (1999) Moment analysis program available on Microsoft Excel® . Xenobio Metab Dispos 14: 286-293.
31. Yamaoka, K, Tanigawara, Y, Nakagawa, T and Uno, T (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4: 879-885.
32. Nishida, Y, Ito, S, Ohtsuki, S, Yamamoto, N, Takahashi, T, Iwata, N et al. (2009). Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem 284: 33400-33408.